CTLA-4 is a negative regulator of T cells activation [145], which improves regulatory T cells (Tregs)-mediated immunosuppression by suppressing CTLs immune function, eventually inducing tumor immune escape and drug resistance [146–148]. Here, CTLA4 is linked to neoplasm.